Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin for Chemotherapy-Induced Peripheral Neuropathy
NCT04205071Phase 1Withdrawn
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of lorcaserin in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Improvement in balance for patients with chronic CIPN at 4 weeks. Planned start Nov 2020; status: withdrawn.
02
Drugs
lorcaserin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04205071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205071.